U. Vitolo

IRCC (Institute for Research and Cancer Cure) Candiolo, Oncology, Faculty Member

Followers

Following

Co-authors

Public Views

I am an hematologist working at Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy. I manage patients affected by hematological malignancies and I am conducting clinical research focusing on lymphoid malignancies. I am spending my leisure time traveling and hiking in the mountains

less

sofia rivera

Richard Hoppe

Andrea Gallamini

Université Nice Sophia Antipolis

The University of Virginia

Deepjyoti Saha

Gauhati University

Karen Rosenspire

Uploads

Papers by U. Vitolo

SP-0024 Aggressive Lymphoma (DLBCL) - when does addition of RT doesn’t make a difference?

Radiotherapy and Oncology, 2019

reactivation, which can be avoided with antiviral prophylaxis. People living with HIV are at high... more reactivation, which can be avoided with antiviral prophylaxis. People living with HIV are at high risk of cancer, and especially lung cancer. There are specific guidelines for the management of patients with HIV and cancer (2). Diabetes mellitus is associated with higher mortality in patients with lung cancer, increasing the risk of cardiovascular and infectious events. Complications of diabetes, such as chronic renal insufficiency and peripheral neuropathy can interfere with the treatment of lung cancer. Frequent need for corticosteroids during chemotherapy requires closed monitoring of glycaemia. Adjuvant durvalumab after chemoradiotherapy has been shown to improve overall survival in stage III NSCLC. Autoimmune diseases or diseases requiring immunosuppressive therapy (including corticosteroids > 10 mg/day) and ILD can preclude their use. The comorbidity burden of patients with stage III NSCLC is high, with a variety of diseases and a frequent association of several comorbidities. A thorough work-up of patients exploring these comorbidities is needed before treatment decision, which should be best taken after treatment optimization of all comorbidities within a multidisciplinary setting References :

Download

$Research paper thumbnail of 48OCC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)$

48OCC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

Annals of Oncology, 2018

Introduction: Patients (pts) with R/R NHL, including follicular lymphoma (FL) and diffuse large B... more Introduction: Patients (pts) with R/R NHL, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) have a poor prognosis with limited 2L and 3L treatment options (MacDonald et al. Curr Oncol 2016). Early relapse (ER) pts with FL experiencing progression within 2 years of initial diagnosis and those double refractory (DR) to both rituximab and chemotherapy have particularly poor outcomes (Casulo et al. J Clin Oncol 2015; Gopal et al. N Eng J Med 2014). CC-122 is a novel oral agent that binds the cereblon ubiquitin ligase complex, resulting in degradation of the hematopoietic transcription factors Aiolos and Ikaros. Preliminary results from CC-122-NHL-001, a phase Ib study of CC-122 in combination with obinutuzumab, have shown promising response rates in pts with R/R B-cell NHL (Michot et al. ASH 2016). Herein, we report updated results for safety and efficacy from CC-122-NHL-001 (NCT02417285) with further 12 months follow up. Methods: Eligible pts age ≥18 years had histologically or cytologically confirmed CD20+ B-cell R/R NHL after ≥1 prior regimen for FL/marginal zone lymphoma (MZL) or after ≥2 regimens and/or autologous stem cell transplant (ASCT) for DLBCL. CC-122 was given orally (5 of 7 d) for 28-d cycles in escalating doses plus a fixed dose of intravenous obinutuzumab 1000 mg on d2, 8, 15 of cycle 1 (c1), and d1 of c2-8, upon informed consent. CC-122 active ingredient in capsule formulation (AIC) 1, 2, 3, and 4 mg and CC-122 formulated capsules (F6) 3 and 4 mg were evaluated in separate cohorts. Primary endpoints included safety and tolerability, non-tolerated dose (NTD), and maximum-tolerated dose (MTD). Response was assessed using the Cheson 2007 criteria every 2 cycles to c6, every 3 cycles to c12, and every 6 cycles thereafter. Results: As of May 1, 2017, 38 pts with R/R B-cell NHL were enrolled in the dose-escalation phase of the study. Tumor types included 19 pts with DLBCL, 18 with FL, and 1 with MZL. Of the 18 pts with FL, 10 (5 DR+ER and 5 ER) were difficult to treat, high-risk pts. Median age was 60 years (range, 26-81), 26 (68%) were male, and 29 (76%) had stage III/IV disease. Of the 19 pts with DLBCL, 8 (42%) had transformed DLBCL, and of the 19 pts with FL/MZL, 8 (42%) relapsed in 1 pt. Three deaths occurred during the study (2 PD; 1 AE-related, tumor flare). Median duration of CC-122 treatment was 23.6 weeks (range, 3.4-87.0), equivalent to 7 cycles (range, 1-22). CC-122 dose reduction or temporary interruption occurred in 12 (32%, all due to AEs) or 32 (84%, 26 due to AEs) pts, respectively. Fifty-five percent of pts had Conclusions: The novel, chemotherapy-free combination of CC-122 and obinutuzumab was well tolerated with promising response rates, and durable remissions in R/R B-cell NHL. The safety profile was consistent with other studies of CC-122, with AEs being mainly hematological and manageable. Notably, subgroup analysis showed that the combination has similar efficacy in the high-risk ER and DR subgroups of RR FL compared with the overall FL population. A CC-122 dose of ≥3 mg with obinutuzumab shows the best response rates to date, with deep response upon prolonged treatment. Expansion part B is currently on-going in both lenalidomide naive and lenalidomide refractory FL pts. Disclosures Doorduijn: Celgene: Honoraria; Roche: Honoraria. Vitolo: Janssen: Honoraria, Membership on an entity9s Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity9s Board of Directors or advisory committees; Gilead: Honoraria; Takeda: Honoraria; Mundipharma: Honoraria. Kersten: Roche: Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Milennium/Takeda: Honoraria, Research Funding; Mundipharma: Honoraria; Gilead Sciences: Honoraria; BMS: Honoraria; Kite Pharma: Honoraria; Amgen: Honoraria; MSD: Honoraria; Novartis Pharmaceuticals Corporation: Honoraria. Chiappella: Teva: Speakers Bureau; Roche: Speakers Bureau; Amgen: Speakers Bureau; Celgene: Speakers Bureau; Janssen: Speakers Bureau; Nanostring: Speakers Bureau; Pfizer: Speakers Bureau. Zinzani: Celgene, Janssen, Gilead, Roche, Takeda, BMS, MSD, Sandoz, Servier, Mundipharma: Speakers Bureau; Merck: Consultancy, Other: Advisory board; Celgene, Roche, Janssen, Gilead, Takeda, BMS, MSD, Servier, Sandoz, Mundipharma: Honoraria. Sarmiento: Celgene Research S.L.: Employment, Equity Ownership. Mosulen: Celgene Institute for Translational Research Europe: Employment. Mendez: Celgene Institute for Translational Research Europe: Employment. Petrarca: Celgene Corporation: Employment, Equity Ownership. Pourdehnad: Celgene Corporation: Employment, Equity Ownership. Hege: Celgene Corporation: Employment, Equity Ownership. Li: Celgene Corp.: Employment. Nikolova: Celgene International Sarl: Employment, Equity Ownership. Ribrag: Epizyme: Honoraria; BMS: Honoraria; MSD: Honoraria;…

Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial

Blood, 2012

1984 Background: Peripheral T-cell lymphomas (PTCL) are characterized by a poor prognosis, conven... more 1984 Background: Peripheral T-cell lymphomas (PTCL) are characterized by a poor prognosis, conventional chemotherapy provides a long-term survival of approximately 25%. Few prospective data suggest that autologous SCT (autoSCT) can improve prognosis when used up-front. Allogeneic SCT (alloSCT) can obtain a durable disease control at relapse in 40% of patients (pts). Based upon these premises, we designed a phase II trial for young pts (age 18 –60 yrs) in which intensified chemo-immunotherapy was used before auto or alloSCT. Transplant type was decided according to the donor availability. Primary endpoint was CR rate at one year after the end of treatment. This was the first prospective trial employing high-dose (hd) chemo-immunotherapy and alloSCT frontline in PTCLs. Methods: 64 pts with newly diagnosed PTCL (ALK-positive ALCL cases were excluded) were included (EudraCT N° 200600423433). Histology was centrally reviewed. The intensified pre-transplant phase consisted of 2 courses of...

Pet‐Driven Radiotherapy in Patients with Low Risk Diffuse Large B‐Cell Lymphoma (DLBCL): The DLCL10 Multicenter Phase 2 Trial by Fondazione Italiana Linfomi (Fil)

Hematological Oncology, 2019

For analysis B, 1,887 (80%) of 2,338 patients were included who received 6x (45%) or 8x (55%) R-C... more For analysis B, 1,887 (80%) of 2,338 patients were included who received 6x (45%) or 8x (55%) R-CHOP. Recipients of 6 cycles, as compared to recipients of 8 cycles, were older (median age, 71 v 61 years; P<0.001), whereas IPI score distribution was not significantly different (P = 0.099). The adjusted risk of mortality was similar between both groups across all age groups (Fig 1B for patients <65 years). Lastly, for analysis C, 897 (48%) of 1,887 patients were included, of whom most received 8x R-CHOP21 (49%) followed by 8x R-CHOP14 (26%), 6x R-CHOP21 (13%), and 6x R-CHOP14 (12%). Recipients of 6 R-CHOP21±2R, as compared to recipients of other regimens, were not older (median age, 55 v 55 years; P = 0.602), but had slightly less often an IPI of ≥3 (24% v 27%; P = 0.004). The adjusted risk of mortality was similar between 6xR-CHOP21±2R and the other regimens (Fig 1C). Conclusion: Our population-based analyses add support to the notion from several RCTs that R-CHOP21 and R-CHOP14, and 6x and 8x R-CHOP are equally effective. Furthermore, 6x R-CHOP21±2R was found to be equally effective compared to all other regimens in all age groups. Therefore, 6xR-CHOP21 (±2R) should be considered the preferred first-line regimen for all patients with advanced-stage DLBCL. The question whether 2R after 6x CHOP21 can be omitted without compromising efficacy remains a topic for future studies.

Download

Improved Survival Outcomes for Patients with Extra-Nodal NK/T Lymphoma: Data from 140 Patients Prospectively Registered in the International T-Cell Project

Hematological Oncology, 2017

primary endpoint) and PFS in patients with all biopsies ≥10% CD30+ (CD30 min ≥ 10%) vs ≥1 biopsy ... more primary endpoint) and PFS in patients with all biopsies ≥10% CD30+ (CD30 min ≥ 10%) vs ≥1 biopsy <10% CD30+ (CD30 min < 10%). Patients were randomized 1:1 to BV 1.8 mg/kg IV, Q3W, or PC for up to 16 three-week cycles. Results: Overall, 125/184 (68%) MF and 44/47 (94%) pcALCL patients were scored as CD30+ at screening evaluation. High inter-lesional variability in CD30 expression was seen in MF patients; 55/125 CD30+ MF patients (44%) had ≥1 biopsy with low (<10%) or undetectable CD30. In total, 100/125 CD30+ MF patients (80%) were eligible and enrolled; 50 per treatment arm. In the BV arm, ORR4 was higher in MF patients with CD30 min ≥ 10% vs <10% (57.1% vs 40.9%); median PFS with BV was higher in the CD30 min < 10% group (27.9 months) than in the CD30 min ≥ 10% group (17.2 months) (Table). ORR4 with BV was greater than PC over all CD30 expression ranges (CD30 min < 5%, 38% vs 13%; CD30 ≥ 5-≤20%, 35% vs 10%; CD30 > 20%, 76% vs 7%, respectively). Conclusions: Notable inter-patient or inter-lesional variability in CD30 expression was seen in MF patients. BV produced highly superior ORR4 and PFS endpoints compared with PC regardless of CD30 min expression level.

Download

$Research paper thumbnail of Retrospective analysis on R‐DHAP/OX and ASCT as salvage treatment for relapsed/refractory high‐risk follicular lymphoma$

Retrospective analysis on R‐DHAP/OX and ASCT as salvage treatment for relapsed/refractory high‐risk follicular lymphoma

Hematological Oncology, 2017

IF-RT was administered with a median dose of 24 Gy (range 20-44 Gy). Bone marrow PCR-BCL2 was pos... more IF-RT was administered with a median dose of 24 Gy (range 20-44 Gy). Bone marrow PCR-BCL2 was positive in 3/41 patients (7%). All patients achieved CR; after a median follow-up of 46 months (range 18-108), all patients remain alive, with only 3 patients relapsing after 18, 26, and 42 months, respectively. Estimated 5-year PFS is 90% with a median PFS not reached (Figure 1). Interestingly, 2 patients experienced controlateral relapse in the irradiated area. No hematological toxicity was reported after R administration, and infusional reaction was mild and manageable. After RT, only transient grade 1-2 mucositis and skin rash were observed. Conclusions: In this study, we suggest R in association with IF-RT could represent a suitable first-line treatment option for early stage FL patients, with higher efficacy and no additional toxicity compared to available published data about RT alone. These promising results need to be confirmed in prospective studies, but could pay the way towards an increasing chance of disease eradication.

Download

MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study

Journal of Clinical Oncology, 1992

PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the ... more PURPOSE The prognosis of advanced-stage diffuse large-cell lymphoma (DLCL) has improved with the use of the third-generation regimens such as methotrexate with leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B). However, different results have been reported. Therefore, we started a cooperative study to confirm the efficacy of MACOP-B. An analysis of prognostic factors was also performed to identify poor-prognosis patients. PATIENTS AND METHODS Between June 1986 and March 1989, 180 patients with advanced-stage DLCL were treated with MACOP-B. MACOP-B was given according to the original scheme. Numerous clinical features possibly predictive for complete response (CR), disease-free survival (DFS), and survival were analyzed in univariate and multivariate analyses. RESULTS One hundred twenty-seven patients (71%) achieved a complete remission, 20 (11%) achieved a partial remission, 24 (13%) had unchanged or progressive disease, and nine (5%) died d...

A Multicentric retrospective analysis on clinical outcomes for elderly patients with stage I-II diffuse large b-cell lymphoma

Journal of Geriatric Oncology, 2014

Lymphoblastic lymphoma in adolescents and adults. Clinical, pathological and prognostic evaluation

European Journal of Cancer and Clinical Oncology, 1986

Sixty-four adult patients with lymphoblasts lymphoma (LB) identified according to Kiel Classifica... more Sixty-four adult patients with lymphoblasts lymphoma (LB) identified according to Kiel Classification were analyzed retrospectively. Three distinct clinical presentations were identified: prevalent abdominal disease (29 pts = 45.3%), prevalent mediastinal disease (14 pts = 21.9%) and prevalent superficial node involvement (21 pts = 32.8%). On histological grounds, the patients with abdominal disease were mainly associated to &quot;Burkitt like&quot; cell lymphoma (55%); patients with mediastinal disease to convoluted cell type (58%); and those with superficial node disease to unclassified cell type (48%). Immunological studies showed a significant correlation between mediastinal disease and T phenotype (P = 0.0011), abdominal disease and B phenotype (P = 0.00042), and between superficial node disease and non-B non-T phenotype (P = 0.00024). Survival was independent of the type of clinical presentation and protocol employed but was correlated with the stage (P less than 0.0005), symptoms (P less than 0.025), bulky disease (P less than 0.025) and bone marrow involvement (P less than 0.025). Furthermore the response to therapy was strongly correlated with prognosis (P less than 0.0001) with 34.5 months median survival for complete responders, 9 months for partial responders, and 3 months for non-responders. Four patients underwent bone marrow transplantation (three autologous and one allogeneic BMT in a patient in leukemic phase); three of them are still in CR (18, 22, and 27 months from the transplant) while one patient had an early relapse and died 3 months later.

PO-0641 Mediastinal B-Cell Lymphoma in Pet-Rituximab Era: Prognostic Impact of Initial Response and Radiation Therapy

Radiotherapy and Oncology, 2012

Purpose/Objective: Medulloblastoma is the pediatric most common brain tumor. Local management of ... more Purpose/Objective: Medulloblastoma is the pediatric most common brain tumor. Local management of this disease includes maximal surgical resection and then craniospinal irradiation (CSI). CSI with a homogeneous dose remains one of the most technically challenging planning processes in radiation oncology. The aim of this study was to report the results of our clinical experience with helical tomotherapy (HT) in pediatric medulloblastoma. Materials and Methods: From May 2007 to July 2010, 21 consecutive pediatric patients (11 male; 10 female) with diagnosis of standard (N = 11) or high risk (N = 10) medulloblastoma were treated with HT. Median age was 5 years old (range, 3 to 14). Two patients were treated with 2 sessions per day (1.3 Gy bifractionated). All the other patients received a standard fractionation regimen with one fraction (1.8Gy) per day. The total dose delivered to the cerebrospinal axis was 23.4 Gy (N = 12), 36 Gy (N = 8), or 39 Gy (N = 2); and 54 Gy to the posterior cranial fossa except for the 2 patients who were treated twice per day (60 Gy). The Kaplan-Meier method was used to provide estimates of the overall survival (OS) and disease-free survival (DFS). Toxicity was evaluated using the Radiation Therapy Oncology Group scale. Results: The median follow-up was 23 months (range, 3 to 58). Median OS was 27 months (range, 6 to 60). There were 2 local failures, 2 distant failures, and 3 both local and distant failures. Twoyear DFS and OS rates were 86% and 91%, respectively. Mean homogeneity index for the brain and the spine were 0.96 and 0.88, respectively. The average dose received by the critical organs in the 23,4 Gy (CSI) + 30.6 Gy (tumor bed) group were: 13.2 Gy on the eyes, 6.8 Gy on the cristalline lens, 24.8 Gy on the optic nerves, 33.4 Gy to the cochleae, 24.7 Gy on the temporo-mandibular joint, 12.4 Gy to the thyroid gland, 4.9 Gy to the heart (median V20 0%), 6.5 Gy to each lung (median V20 1.2%), 6.1 Gy to the liver (median V20 0.005%), 7.4 Gy to each kidney (median V20 0.1%), and 8.6 Gy to the bowel (median V20 1.5%). For the group of 36/39 Gy (CSI) + 18/21 Gy (tumor bed), the average dose were: 19.6 Gy on the eyes, 7.4 Gy on the cristalline lens, 37.6 Gy on the optic nerves, 41.1 Gy to the cochleae, 42.2 Gy on the temporo-mandibular joint, 19.7 Gy to the thyroid gland, 12.2 Gy to the heart (median V20 3%) , 9.5 Gy to each lung (median V20 8%), 9.3 Gy to the liver (median V20 1.5%), 9.8 Gy to each kidney (median V20 1.5%), and 12 Gy to the bowel (median V20 9%). Early severe (grade ≥ 3) toxicity was mostly hematologic (47.6% of patients) with 4 grade IV neutropenia, and 1 grade IV thrombopenia. No patient experienced any severe long-term toxicity. Conclusions: HT for pediatric medulloblastoma is feasible and has a good tolerance and outcome. In our series, no patient had long-term severe toxicity. HT seems to be ideally suited to plan such long and complex-shaped target volumes, avoiding any junction, field-matching and abutment dosimetry.

Download

46 Significant reduction of second breast cancer risk in patients treated with involved nodes radiation therapy for early stage Hodgkin's lymphoma

European Journal of Cancer Supplements, 2010

Results: Characteristics of 6 enrolled Eypatients were: M/F: 3/3; median age: 56 yrs (range 54−73... more Results: Characteristics of 6 enrolled Eypatients were: M/F: 3/3; median age: 56 yrs (range 54−73); 4/6 patients received two cycles of MTX-HD, 2/6 only one cycle because of hepatic and renal toxicity. Three out of six patients received TMZ at the dose of 50 mg/mq/die and 3/6 at the dose of 60 mg/mq/die. All patients completed RT-CT without interruptions. Only one patient presented grade-2 treatment related acute haematological toxicity. Median follow-up was 11.5 months (range 5−30). No patient experienced MTD. Conclusion: RTCT with concomitant TMZ at a dose of 60 mg/mq/die is well tolerated; further dose escalation is ongoing to define MTD before prospective phase II study. 45 High frequency and prognostic importance of autoimmune hemolytic anemia in splenic marginal zone lymphoma

Download

Probability of cure in elderly Hodgkin's disease patients

Haematologica

Elderly Hodgkin's disease patients have a poor prognosis. The question arises whether these p... more Elderly Hodgkin's disease patients have a poor prognosis. The question arises whether these patients need aggressive treatment or a palliative strategy. So far, as a consequence of the scarcity of trials designed for them, useful information can be obtained only by retrospective analyses. We retrospectively studied clinical data from 567 patients recorded from 1982 to 1989 in the Piemonte Hodgkin's Disease Register (PHDR). The 65 patients over 65 years of age were compared to younger ones. We analyzed the role of disease independently of confounding variables, mainly inadequacy of staging and/or treatment, comorbidity and toxicity. In the elderly comorbidity was as high as 35%. Forty elderly patients (60%) entered a suboptimal plan with a low degree of aggressivity, which was different from the usual PHDR protocol. Elderly patients also had a high proportion of subsequent protocol interruptions (25%). Chemotherapy dose intensity was negatively affected by advanced age (p &lt...

Burkitt's lymphomas in adults: retrospective analysis of 30 cases treated with two different schemes

Haematologica, 1999

T acute lymphoblastic leukemia in ataxia-telangiectasia. Report of a case characterized by monoclonal antibodies

Haematologica

CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity

Haematologica

Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma

Haematologica

An effective second-line treatment for intermediate and high grade non-Hodgkin's lymphoma is ... more An effective second-line treatment for intermediate and high grade non-Hodgkin's lymphoma is greatly needed since 30% of patients do not achieved complete remission (CR) and another 20% to 30% of the CRs will eventually relapse. A four-drug combination with Mitoxantrone, Etoposide, Cisplatin and Dexamethasone (MEPD) was devised for the treatment of patients with relapsing or refractory non-Hodgkin's lymphoma (NHL). So far 22 patients with intermediate or high grade NHL have entered the study. All patients were previously treated with doxorubicin based regimens. Seven patients obtained a complete remission (CR), 3 a partial remission (PR), 4 a minor response (MR) and 8 were treatment failures (F). Thus, an overall response rate of 45% has been achieved. To date three of the complete responders have relapsed at 3, 6 and 15 months. Four patients are still in CR at +2, +4, +9 and +17 months, respectively. Patients with relapsing lymphoma responded better than those with primary ...

MACOP-B for advanced stage large cell lymphoma (DLCL). More is better? Italian Multiregional Cooperative Study Group (IMCSGL)

Leukemia, 1991

A study of the predictive value for CR, DFS and OS of the presenting features was carried out on ... more A study of the predictive value for CR, DFS and OS of the presenting features was carried out on 180 patients with advanced stage DLCL treated with MACOP-B between June 1986 and March 1989. A multivariate regression analysis identified LDH level, bone marrow involvement and tumor burden as independent risk factors with a 4 year survival rate of 79%, 58% and 28% respectively. Therefore MACOP-B proved to be an adequate treatment for the first two groups of patients but not for the third which requires a more aggressive treatment. A sequential single drug high dose chemotherapy with collection of peripheral blood stem cell program followed by bone marrow harvesting, super-intensive radio-chemotherapy and bone marrow transplant has been activated. Seven patients have been so far enrolled: preliminary results demonstrated the feasibility of the program. A larger number of cases and a longer follow-up is required for assessing the efficacy of this approach.

Multicenter prospective randomized GITMO trial comparing high dose sequential chemotherapy with autografting and CHOP both supplemented with Rituximab as frontline therapy for high-risk follicular lymphoma (FL) patients: An interim analysis

The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma

Leukemia, 2014

on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for ... more on behalf of the European MCL Network and the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation The role of both autologous (autoSCT) and allogeneic stem cell transplantation (alloSCT) in the management of mantle cell lymphoma (MCL) remains to be clarified. We conducted a consensus project using the RAND-modified Delphi consensus procedure to provide guidance on how SCT should be used in MCL. With regard to autoSCT, there was consensus in support of: autoSCT is the standard first-line consolidation therapy; induction therapy should include high-dose cytarabine and Rituximab; complete or partial remission should be achieved before autoSCT; Rituximab maintenance following autoSCT is not indicated; and omission of autoSCT in 'low-risk' patients is not indicated. No consensus could be reached regarding: autoSCT in the treatment of relapsed disease following non-transplant therapy; the value of positron emission tomography scanning and minimal residual disease (MRD) monitoring; in vivo purging with Rituximab; total body irradiation conditioning for autoSCT; and preemptive Rituximab after autoSCT. For alloSCT, consensus was reached in support of: alloSCT should be considered for patients relapsing after autoSCT; reduced intensity conditioning regimens should be used; allogeneic immunotherapy should be used for MRD eradication after alloSCT; and there is a lack of prognostic criteria to guide the use of alloSCT as first-line consolidation. No consensus was reached regarding the role of alloSCT for relapsed disease following non-transplant therapy.

Download

Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma

Leukemia & Lymphoma, 2007

The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment o... more The Intergruppo Italiano Linfomi started, in 1996, a randomized trial for the initial treatment of elderly patients (older than 65 years) with Diffuse Large B-Cell Lymphoma (B-DLCL) comparing 6 courses of Mini-CEOP vs 8 weeks of P-VEBEC chemotherapy. Study objectives were survival, response and Quality of Life (QoL). Two hundred and thirty-two patients were evaluable for final analysis. Complete Response (CR) and Overall Response Rates (ORR) were 54% vs 66% (p = 0.107) and 90% vs 78% (p = 0.021) for P-VEBEC and Mini-CEOP, respectively. With a median follow-up of 72 months, the 5-year Overall Survival (OS), Relapse Free Survival (RFS), and Failure Free Survival (FFS) were 32%, 52%, and 21%, respectively. Subjects achieving a CR showed improvement of QoL regardless of treatment arm. Both Mini-CEOP and P-VEBEC determined a similar outcome for elderly patients with B-DLCL, with a third of patients alive after more than 6 years of follow-up. Both regimens can be considered equally for combination treatment with anti-CD20 monoclonal antibody.

SP-0024 Aggressive Lymphoma (DLBCL) - when does addition of RT doesn’t make a difference?

Radiotherapy and Oncology, 2019

Download

$Research paper thumbnail of 48OCC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)$

48OCC-122, a novel cereblon-modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R/R) B-cell non-hodgkin lymphoma (NHL)

Annals of Oncology, 2018